Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Baclofen for Alcohol Use Disorder

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: November 2018

Workgroups: Substance Use Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that, compared with placebo, baclofen has little to no effect in treating alcohol use disorder. Researchers found that baclofen makes little to no difference to study participants who dropped out of treatment, dropped out because of side effects, or had at least 1 side effect. They found that it probably makes little difference in the number of participants who start drinking again or in how much or how often they drink. Researchers also found that baclofen increased bad outcomes like depression, vertigo, sleepiness, numbness, and muscle stiffness.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of people who had alcohol use disorder in the past year — SU‑13
Little or no detectable change

Suggested Citation

1.

Minozzi. S, Saulle, R. & Rösner, S. (2018) Baclofen for alcohol use disorder. Cochrane Database of Systematic Reviews, 2018 (11). DOI: 10.1002/14651858.CD012557.pub2.